Together, these findings indicate that elimination of KCa3.1 ameliorated the pathological hallmarks of AD in KCa3.1−/−/APP/PS1 mice, such as neuronal loss, microglial activation, RA, and neuroinflammation. This evidence concerns the gene PSEN1 and Alzheimer disease.